- Conditions
- Arthritis, Psoriatic
- Interventions
- placebo, ustekinumab 45 mg, ustekinumab 90 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 312 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Los Angeles, California + 22 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 625–648
of 701
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Interventions
- Ibrutinib, Next-line ibrutinib
- Drug
- Lead sponsor
- Pharmacyclics LLC.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2023
- U.S. locations
- 16
- States / cities
- Duarte, California • La Jolla, California • Stanford, California + 13 more
- Conditions
- Healthy
- Interventions
- Seltorexant
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Colitis, Ulcerative
- Interventions
- Placebo, Golimumab 50 mg, Golimumab 100 mg, Golimumab 200 mg
- Biological
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,228 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2015
- U.S. locations
- 96
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 93 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- JNJ-64565111, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Chula Vista, California • Miami, Florida
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab, VELCADE (Bortezomib), Dexamethasone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 498 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2024
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Stamford, Connecticut + 14 more
- Conditions
- Thrombocytopenia, Neonatal Alloimmune
- Interventions
- Nipocalimab, Intravenous immunoglobulins (IVIG), Prednisone
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Sacramento, California • Aurora, Colorado + 10 more
- Conditions
- Healthy
- Interventions
- JNJ-42165279 (100 mg), Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Multiple Myeloma
- Interventions
- Cilta-cel, Talquetamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 5
- States / cities
- Iowa City, Iowa • Louisville, Kentucky • Detroit, Michigan + 2 more
- Conditions
- Major Depressive Disorder
- Interventions
- Placebo, Ketamine
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 68 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 13
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Centennial, Colorado + 10 more
- Conditions
- Healthy
- Interventions
- JNJ-39439335
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years · Male only
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Crohn Disease
- Interventions
- Icotrokinra, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,092 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2032
- U.S. locations
- 61
- States / cities
- Chandler, Arizona • Litchfield Park, Arizona • Scottsdale, Arizona + 49 more
- Conditions
- E.Coli Infections
- Interventions
- Not listed
- Lead sponsor
- MJM Bonten
- Other
- Eligibility
- 60 Years and older
- Enrollment
- 4,479 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
- Interventions
- Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
- Drug · Device
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Schizophrenia
- Interventions
- Paliperidone IR (Period 1), Paliperidone palmitate F015 (Panel A: treatment group 1), Paliperidone palmitate F015 (Panel A: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 1), Paliperidone palmitate F015 (Panel B: treatment group 2), Paliperidone palmitate F015 (Panel B: treatment group 3), Paliperidone palmitate F015 (Panel B: treatment group 4), Paliperidone palmitate F015 (Panel B: treatment group 5), Paliperidone palmitate F016, Paliperidone palmitate F015 (Panel D: treatment group 1), Paliperidone palmitate F015 (Panel D: treatment group 2), Paliperidone palmitate F015 (Panel D: treatment group 3), Paliperidone palmitate F015 (Panel D: treatment group 4)
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2014
- U.S. locations
- 10
- States / cities
- Little Rock, Arkansas • Cerritos, California • Garden Grove, California + 7 more
- Conditions
- Metastatic Castration-resistant Prostate Neoplasms, Metastatic Hormone-sensitive Prostate Cancer
- Interventions
- Pasritamig, Cetrelimab, Cabazitaxel, Docetaxel, Apalutamide, Enzalutamide, Darolutamide, Abiraterone acetate plus prednisone (AAP), Lutetium Lu-177 vipivotide tetraxetan, JNJ-101556143
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 7
- States / cities
- Sarasota, Florida • Grand Rapids, Michigan • St Louis, Missouri + 4 more
- Conditions
- Rheumatoid Arthritis
- Interventions
- Placebo, JNJ-38518168 (3 mg), JNJ-38518168 (10 mg), JNJ-38518168 (30 mg), Methotrexate
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 9
- States / cities
- Huntsville, Alabama • Gilbert, Arizona • Covina, California + 6 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Glimepiride, Canagliflozin (JNJ-28431754), Metformin
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 43
- States / cities
- Calera, Alabama • Gilbert, Arizona • Mesa, Arizona + 40 more
- Conditions
- Advanced Stage Solid Tumors
- Interventions
- JNJ-95437446, Amivantamab
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 4
- States / cities
- Sarasota, Florida • New York, New York • Nashville, Tennessee + 1 more
- Conditions
- Lupus Erythematosus, Cutaneous, Lupus Erythematosus, Systemic, Lupus Erythematosus, Discoid
- Interventions
- No intervention, skin biopsy, No intervention, blood collection, No intervention, urine collection
- Procedure
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 29 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 2
- States / cities
- Indianapolis, Indiana • Dallas, Texas
- Conditions
- Healthy
- Interventions
- ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 59 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Relapsed or Refractory Multiple Myeloma, Previously Treated Amyloid Light-chain (AL) Amyloidosis
- Interventions
- JNJ-79635322
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2030
- U.S. locations
- 9
- States / cities
- Duarte, California • Irvine, California • San Francisco, California + 5 more
- Conditions
- Pharmacology
- Interventions
- Abiraterone: Treatment A, Abiraterone: Treatment B, Abiraterone: Treatment C, Abiraterone: Treatment D
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years to 35 Years · Male only
- Enrollment
- 51 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2012
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- Non-Small-Cell Lung Cancer
- Interventions
- Amivantamab, Lazertinib, Carboplatin, Pemetrexed
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 751 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2027
- U.S. locations
- 17
- States / cities
- Duarte, California • La Jolla, California • Orange, California + 14 more